BioSpace News Archive

Iovance Biotherapeutics, Inc. announced that on July 20, 2023, the Company approved the grant of inducement stock options covering an aggregate of 71,800 shares of Iovance’s common stock to 8 new non-executive employees.

AgeX and Juvenescence entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans.

The U.S. Food and Drug Administration is working closely with Pfizer to assess the impact of the damage at Pfizer’s Rocky Mount, North Carolina, facility.

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the second quarter of 2023 after the market close on Tuesday, August 8, 2023.